



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	172165	BLOOMS MSM 750 WITH GINGER & DEVIL'S CLAW
ARTG entry for	Medicine Listed	
Sponsor	Phytologic Holdings Pty Limited	
Postal Address	PO Box 6193, Alexandria, NSW, 2015 Australia	
ARTG Start Date	10/06/2010	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . BLOOMS MSM 750 WITH GINGER & DEVIL'S CLAW

Product Type	Single Medicine Product	Effective Date	12/02/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Maintain/support general health and wellbeing
- Anti-inflammatory/relieve inflammation
- Analgesic/Anodyne/relieve pain
- Decrease/reduce/relieve mild rheumatic aches and pains
- Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis
 - Linked indication - Decrease/reduce/relieve mild joint aches and pains
 - Linked indication - Decrease/reduce/relieve mild joint stiffness
 - Linked indication - Decrease/reduce/relieve mild joint pain/soreness
 - Linked indication - Decrease/reduce/relieve mild joint inflammation/swelling
- Helps maintain/support joint cartilage health
- Decrease/reduce/relieve mild joint inflammation/swelling
- Maintain/support joint mobility/flexibility
- Decrease/reduce/relieve mild joint stiffness
- Maintain/support healthy digestion
- Decrease/reduce/relieve symptoms of indigestion/dyspepsia
- Relieve digestive discomfort
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Decrease/reduce/relieve muscle pain/ache/soreness after exercise
- Aid/assist/helps post exercise recovery
- Maintain/support skin health

Indication Requirements

- Product presentation must only refer to mild joint symptoms.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- Product presentation must not imply or refer to serious immunological diseases.

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Product presentation must only refer to mild rheumatic aches/pains.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.

Product presentation must not imply or refer to any form of arthritis or osteoarthritis unless qualified as mild.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

dimethyl sulfone	750 mg
Harpagophytum procumbens root Extract dry concentrate standardised	10 mg
Equivalent: Harpagophytum procumbens (Dry)	25 mg
Zingiber officinale root Extract dry concentrate	40 mg
Equivalent: Zingiber officinale (Dry)	1 g

Other Ingredients (Excipients)

hypromellose

magnesium stearate

maltodextrin

purified water

silicon dioxide

sorbitol

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary